Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 39,800 shares, an increase of 26.3% from the December 31st total of 31,500 shares. Based on an average daily trading volume, of 569,300 shares, the short-interest ratio is currently 0.1 days.

Astellas Pharma Stock Performance

Shares of ALPMY opened at $9.68 on Monday. The firm has a market capitalization of $17.52 billion, a PE ratio of 46.10 and a beta of 0.34. The company has a quick ratio of 0.86, a current ratio of 1.10 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $9.87 and a 200 day moving average price of $10.97. Astellas Pharma has a 52-week low of $9.05 and a 52-week high of $13.14.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.